$BLAC
Bellevue Life Sciences Acquisition Corp.

2023 Q3 Form 10-Q Financial Statement

#000089843223000624 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $410.4K $280.3K $10.00K
YoY Change 1952.16% 28267.71%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $410.4K $280.3K $10.00K
YoY Change 1952.16% 28267.71%
Operating Profit
YoY Change
Interest Expense $618.5K $810.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $208.1K $530.0K -$10.00K
YoY Change -1140.35%
Income Tax $129.9K $228.6K
% Of Pretax Income 62.42% 43.13%
Net Earnings $78.18K $301.5K -$10.00K
YoY Change -490.92% -30612.55%
Net Earnings / Revenue
Basic Earnings Per Share $0.01 $0.03
Diluted Earnings Per Share $0.01 $0.03 $0.00
COMMON SHARES
Basic Shares Outstanding 9.055M shares 9.055M shares
Diluted Shares Outstanding 9.055M shares 9.055M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.96K $0.00 $120.0K
YoY Change -17.2% -100.0%
Cash & Equivalents $57.96K $1.181K $124.5K
Short-Term Investments
Other Short-Term Assets $24.46K $60.00K
YoY Change
Inventory
Prepaid Expenses $24.46K $57.80K
Receivables
Other Receivables
Total Short-Term Assets $82.41K $58.98K $124.5K
YoY Change 17.73% -15.75% 2517.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $72.05M $71.44M
YoY Change
Other Assets $0.00 $0.00 $1.100M
YoY Change -100.0% -100.0%
Total Long-Term Assets $72.05M $71.44M $1.101M
YoY Change 6510.46% 7115.71% 57.26%
TOTAL ASSETS
Total Short-Term Assets $82.41K $58.98K $124.5K
Total Long-Term Assets $72.05M $71.44M $1.101M
Total Assets $72.14M $71.49M $1.226M
YoY Change 6118.66% 6644.76% 73.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $500.3K $270.0K $30.00K
YoY Change 2401.75%
Accrued Expenses $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K $0.00 $1.200M
YoY Change -77.78% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.105M $541.4K $1.263M
YoY Change -7.13% -48.93% 78.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.105M $541.4K $1.263M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.175M $2.611M $1.263M
YoY Change 166.82% 146.36% 78.64%
SHAREHOLDERS EQUITY
Retained Earnings -$2.455M -$2.095M -$62.51K
YoY Change 130.49%
Common Stock $216.00 $216.00 $173.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.455M -$2.095M -$37.51K
YoY Change
Total Liabilities & Shareholders Equity $72.14M $71.49M $1.226M
YoY Change 6118.66% 6644.76% 73.86%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income $78.18K $301.5K -$10.00K
YoY Change -490.92% -30612.55%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$143.2K -$350.0K $0.00
YoY Change -1532.2% 3400.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.500K $0.00
YoY Change
Cash From Investing Activities $2.500K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K 0.000 50.00K
YoY Change -2100.0% -100.0% -600.0%
NET CHANGE
Cash From Operating Activities -143.2K -350.0K 0.000
Cash From Investing Activities 2.500K 0.000
Cash From Financing Activities 200.0K 0.000 50.00K
Net Change In Cash 56.78K -350.0K 50.00K
YoY Change 1040504503751812000.0% -600.0% -600.0%
FREE CASH FLOW
Cash From Operating Activities -$143.2K -$350.0K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-41390
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5052822
dei Entity Address Address Line1
EntityAddressAddressLine1
10900 NE 4th Street
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
216 usd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellevue
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98004
dei City Area Code
CityAreaCode
425
dei Local Phone Number
LocalPhoneNumber
635-7700
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9055000 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1181 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124501 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
57795 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
58976 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124501 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1101353 usd
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
71435530 usd
CY2023Q2 us-gaap Assets
Assets
71494506 usd
CY2022Q4 us-gaap Assets
Assets
1225854 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
266485 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
257886 usd
CY2022Q4 blac Accrued Offering Costs Current
AccruedOfferingCostsCurrent
12362 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1200000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
541371 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1263362 usd
CY2023Q2 blac Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2070000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2611371 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1263362 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2094725 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62508 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2094509 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71494506 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1225854 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2120 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2246 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-988 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3234 usd
us-gaap Profit Loss
ProfitLoss
-411769 usd
us-gaap Profit Loss
ProfitLoss
1114 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
280273 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
988 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
558375 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1114 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-280273 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-988 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-558375 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1114 usd
CY2023Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
810302 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1228030 usd
CY2023Q2 us-gaap Other Income
OtherIncome
810302 usd
us-gaap Other Income
OtherIncome
1228030 usd
CY2023Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
530029 usd
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-988 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
669655 usd
us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-1114 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
228565 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
257886 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
301464 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-988 usd
us-gaap Net Income Loss
NetIncomeLoss
411769 usd
us-gaap Net Income Loss
NetIncomeLoss
-1114 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9055000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7133177 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9055000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7196575 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1500000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2023Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1236527 usd
CY2023Q1 blac Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-7439560 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
110305 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1830236 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-565737 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
301464 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2094509 usd
us-gaap Interest Income Interest Earning Asset Increase Decrease
InterestIncomeInterestEarningAssetIncreaseDecrease
1228030 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
57795 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
220123 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5959 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
257886 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-396047 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7073 usd
CY2023Q2 us-gaap Assets Held In Trust
AssetsHeldInTrust
70207500 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70207500 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59670000 usd
CY2023Q2 us-gaap Offering Costs Partnership Interests
OfferingCostsPartnershipInterests
1447273 usd
CY2022Q2 us-gaap Offering Costs Partnership Interests
OfferingCostsPartnershipInterests
430510 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70480227 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76490 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-123320 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
69417 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4757 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1181 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74174 usd
us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2070000 usd
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
148512 usd
CY2023Q2 blac Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1 pure
blac Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
0.80 pure
blac Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50 pure
CY2023Q2 us-gaap Assets Held In Trust
AssetsHeldInTrust
70207500 usd
us-gaap Debt Instrument Redemption Description
DebtInstrumentRedemptionDescription
The Company will provide its holders of the outstanding shares of its Common Stock sold in the Initial Public Offering (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares (as described in Note 1) for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.175 per Public Share plus any pro rata interest then in the Trust Account, net of taxes payable). The per-share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).
blac Redemption Limit Percentage
RedemptionLimitPercentage
0.15 pure
blac Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
blac Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000 usd
CY2023Q2 us-gaap Cash
Cash
1181 usd
CY2023Q2 us-gaap Debt Current
DebtCurrent
482395 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="color: #231F20; font-family: 'Times New Roman', serif; font-weight: bold;"><span>Concentration of Credit Risk</span></div><div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif;"><span>Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="color: #231F20; font-family: 'Times New Roman', serif; font-weight: bold;"><span>Use of Estimates</span></div><div style="text-align: justify; text-indent: 36pt; color: #231F20; font-family: 'Times New Roman', serif;"><span>The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.</span></div><div style="text-align: justify; text-indent: 36pt; color: #231F20; font-family: 'Times New Roman', serif;"><span>Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></div><div style="font-family: 'Times New Roman',serif;"><br/> </div>
CY2023Q2 us-gaap Cash
Cash
1181 usd
CY2022Q4 us-gaap Cash
Cash
124501 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 blac Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share
CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
7330000 shares
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0 usd
CY2023Q2 blac Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2 pure
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000 shares
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7330000 shares
CY2023Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
71435530 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001840425

Files In Submission

Name View Source Status
blac-20230630_cal.xml Edgar Link unprocessable
0000898432-23-000624-index-headers.html Edgar Link pending
0000898432-23-000624-index.html Edgar Link pending
0000898432-23-000624.txt Edgar Link pending
0000898432-23-000624-xbrl.zip Edgar Link pending
blac-20230630.htm Edgar Link pending
blac-20230630.xsd Edgar Link pending
exh31-1.htm Edgar Link pending
exh31-2.htm Edgar Link pending
exh32-1.htm Edgar Link pending
exh32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blac-20230630_def.xml Edgar Link unprocessable
blac-20230630_lab.xml Edgar Link unprocessable
blac-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blac-20230630_htm.xml Edgar Link completed